natgillin/translations-raw huggingface dataset:
The binder according to claim 38, wherein the component having available aluminum is selected from the group consisting of soluble alkali aluminates, amorphous aluminum hydroxide, calcium aluminate cement, and geopolymer binder. The binder according to claim 23, wherein the ternesite clinker and the calcium sulfoaluminate clinker are ground together or separately to degrees of fineness (according to Blaine) in the range of 2000 to 10000 cm2/g, either with or without sulfate carriers in the form of alkaline and/or alkaline earth sulfates. 
Vezivo sukladno barem jednom od zahtjeva 3 do 9, naznačeno time što su ternesit klinker i kalcij sulfoaluminat klinker zajedno ili odvojeno smljeveni do stupnja finoće (sukladno Blaineu) opsega od 2000 do 10000 cnr/g, poželjno opsega od 3000 do 6000 cm?/g i poželjnije od 4000 do 5000 cm?/g, sa ili bez sulfatnih nositelja u obliku alkalijski i/ili zemno alkalijskih sulfata, poželjno u obliku gipsa i/ili hemihidrata i/ili magnezij sulfata.
It therefore is not lying flat, but is moving fast through all parts of a cross-section of the pneumatic conduit. 
Zbog toga ona ne leži ravno, nego se brzo kreće kroz sve dijelove poprečnog
US2003/0089710 A1 describes an electrical box into which a one-piece recessed faceplate is inserted, said faceplate allowing for the adjustment of the distances between the outward surface of the electrical instrumentality installed into the electrical box and the flange positioned at the front of said faceplate. 
US2003/0089710 A1, koja predstavlja najbliže stanje tehnike, opisuje kutiju za električne komponente u kutiji za električne komponente, u koju je instalirana uvučena čeona ploča koja je načinjena od jednog komada, pri čemu čeona ploča omogućava namještanje razmaka između vanjske strane površine električne instrumentacije koja je instalirana u kutiju za električne komponente i prirubnice koja je postavljena na prednju stranu navedene čeone ploče.
15, 1984) that allows conducting the simultaneous heating and irradiation of oil stratum in the well bottom zone with ultrasound using a magnetostrictive radiator, which increases the inflow of oil into a well. 
koji omogućuje provođenje istovremenog zagrijavanja i ozračivanja naslaga nafte u zoni dna izvora ultrazvukom, uporabom magnetostriktivnog radijatora, što povećava ulaz nafte u izvor.
Also, the coating inhibits fungal mold growth and with appropriate additives inhibits bacterial growth an the surface of the produce. 
Također, oblaganje inhibira rast gljivica i sa odgovarajućim aditivima inhibira rast bakterija na površini proizvoda.
The compound according to claim 1 wherein R6-R10 are H with the proviso that one of the groups R7, R8 or R9 is the sulfonyl group with R1. 
Spoj prema zahtjevima 1-12, naznačen time što R4-Ry su H s uvjetom da je jedna od skupina R;, Rg ili Ro sulfonil skupina s Ri.
The ratio of silicate to potassium Si2O:K2O can range from 2:1 to 6:1, more preferably from 2:1 to 3:1, and most preferably from 2.4:1 to 2.8:1. 
Gusta smjesa 1z patentnog zahtjeva 2, pri čemu kalijev silikat obogaćen litijem sadrži kalij i litij u masenom omjeru 7:1 do 11:1 kao K20:L120, i nadalje gdje je maseni omjer silikata prema kaliju od 2.4:1 do 2.8:1 kao SiO»:K20.
physico-chemical pre-treatment of lignocellulosic biomass to obtain a pre-treated slurry; 
fizičko-kemijske prethodne obrade lignocelulozne biomase kako bi se dobila prethodno obrađena kaša; b)
A combination according to claim 1 wherein R1 is selected from H, -COR8, or substituted or unsubstituted alkyl. 
Sastav prema zahtjevu 1 naznačen time da R, je odabran od H, -COR, ili alkila.
The isolated monoclonal antibody or antigen binding fragment of claim 1, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 27. 
Protutijelo ili njegov za antigen vezni fragment prema zahtjevu 6, gdje varijabilni teški lanac obuhvaća SEQ ID NO:27.
An antibody or antigen binding fragment thereof as defined in any one of claims 1 to 7, or an antibody drug conjugate as defined in claim 8 or 9 for use in a method of treating cancer. 
Konjugat antitijela i lijeka definiran prema jednom od patentnih zahtjeva 1 do 18 za uporabu u liječenju raka u subjektu.
In another aspect, the invention features a method of improving an impaired sensory neural response by administering, to a subject that exhibits an impaired sensory neural response, an amount of a polypeptide effective to improve the impaired response, wherein the polypeptide contains an amino acid sequence that is at least 80% identical to amino acids 15-113 of SEQ ID NO:1, and wherein the polypeptide, when dimerized, binds to a complex containing GFRa3 and RET. 
Polipeptid za uporabu u vidu lijeka za regeneriranje živčanih vlakana kod subjekta koji ispoljava narušen senzorni živčani odgovor, naznačen time, što polipeptid sadrži aminokiselinsku sekvencu koja je najmanje 80% identična sa amino.kiselinama 15-113 SEQ ID NO:1, 1 gdje se polipeptid, kada se dimerizira, vezuje u kompleks koji sadrži GFR93 i RET.
The process according to claim 2 wherein the heating phase precedes the cooling phase. 
Postupak prema zahtjevu 2 naznačen time da faza grijanja prethodi fazi hlađenja.
the block having a 1,4- cis structure has a glass transition temperature (Tg) lower than or equal to - 100°C, a melting point (Tm) lower than or equal to - 2°C and a crystallization temperature (Tc) lower than or equal to -25°C; 
blok koji ima 1,4-cis strukturu ima temperaturu stakljenja (T,) ispod ili jednaku 00 "€, talište (T,,) ispod ili jednako -2 *C i temperaturu kristalizacije (T.) ispod ili jednaku -25 *C;
The bag according to claim 14, wherein the pharmaceutical product is selected from the group consisting of: azacytidine, belinostat, bendamustine, brentuximab vedotin, bleomycin, bortezomib, busulfan, carboplatin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin, decitabine, deferoxamine, doxorubicin, epirubicin hydrochloride, fludarabine, fotemustine, fulvestrant, gemcitabine, idarubicin, ifosfamide, irinotecan hydrochloride, ixabepilone, melphalan, methotrexate, oxaliplatin, paclitaxel, pemeterxed, pentostatin, raltitrexed, romidepsin, temozolomide, thiotepa, topotecan, trabectedin, trastuzumab, and vinblastine. 
Upotreba u skladu s bilo kojim prethodnim patentnim zahtjevom, naznačena time, da je citotoksični lijek odabran iz skupine koju čine: azacitidin, belinostat, bendamustin, brentuksimab vedotin, bleomicin, bortezomib, busulfan, karboplatin, ciklofosfamid, citarabin, dakarbazin, daktinomicin, daunorubicin, decitabin, deferoksamin, doksorubicin, epirubicin hidroklorid, fludarabin, fotemustin, fulvestrant, gemcitabin, idarubicin, ifosfamid, irinotekan hidroklorid, iksabepilon, melfalan, metotreksat, oksaliplatin, paklitaksel, pemetreksed, pentostatin, raltitreksed, romidepsin, temozolomid, tiotepa, topotekan, trabektedin, trastuzumab i vinblastin.
The method of claim 1, wherein R2 is phenyl or thienyl, wherein the phenyl or thienyl is optionally substituted with one, two, or three members independently selected from: halo, C1-5alkyl, and C1-5haloalkyl. 
je fenil ili tienil, pri čemu fenil ili tienil je opcionalno supstituiran s jednim, dva, ili tri člana nezavisno izabranih između: halo, C1-5alkil, i C1-5haloalkil;
A polynucleotide encoding the VH domain of SEQ. 
Polinukleotid koji kodira VH domenu sa SEQ.
A represents a monocyclic or bicyclic C6-C10 aryl or a monocyclic or bicyclic C5-C12 heteroaryl group containing 1 to 3 ring heteroatoms; 
A predstavlja monocikličku ili bicikličku Cg-Crgarilnu ili monocikličku ili bicikličku Cs-C,o>heteroarilnu skupinu koja sadrži 1 do 3 prstenska heteroatoma;
The fuel gas supply system of a vessel according to claim 1 wherein the boil-off gas is in thermal communication with the LNG to minimize the capacity of the boil-off gas reliquefaction apparatus. 
Sustav dobave pogonskog plina za plovilo prema zahtjevu 1 naznačen time da je ispareni plin u termalnoj komunikaciji s LNG kako bi se smanjio kapacitet uređaja za ukapljivanje isparenog plina.
Known forms of inhalers (1) provide an attachment of the cap to the mouthpiece or main body of the inhaler by means of a strap or string. 
Poznati oblici inhalatora (1) imaju poveznicu zatvarača s kljunom ili glavnim tijelom inhalatora pomoću vrpce ili lančića.
determining a second MACERS for a subject based upon, at least in part, the ratio of a third level of soluble ST2 in the subject at a third time (ST2 T2) to the first level of soluble ST2 in the subject at the first time (ST2 T0), in addition to a weighted natural logarithm of a level of NT-proBNP in the subject at the third time (NP T2) according to the following formula: EPMATHMARKEREP wherein a is a weighing factor; 
Postupak patentnog zahtjeva 1, dalje obuhvaća: dobivanje prve razine od ST2 kod osobe pri prvoj zabilježenoj incidenciji, kako bi se determinirao ST2 T0; dobivanje druge razine od ST2 kod osobe pri drugoj zabilježenoj incidenciji, kako bi se determinirao ST2 T1; i dobivanje razine od of NT-proBNP kod osobe pri drugoj zabilježenoj incidenciji, kakao bi se determinirao NP T1.
switching the changeover switch to the first position. 
u koraku j) sklopka za prebacivanje (2) prebacuje se u prvi položaj .
a sump in the floor of the sludge drying bed to the front of the sluice door. 
(D taložnik (3) u podu ležišta za sušenje mulja (14) do prednje strane izljevnih vrata (1).
The residue was purified by PTLC (SiO2) using 30% ethyl acetate-hexanes to give the desired compound (16 mg). 
Ostatak se pročisti PTLC (SiO2) uz uporabu 30% etil acetat-heksana da bi se dobio traženi spoj (16 mg).
The DNA polymerase chimera according to any of claims 1 to 5, wherein the connecting amino acid sequence of (b) is SEQ ID NO: 5 or SEQ ID NO: 6. 
DNK polimeraza himera prema bilo kojem zahtjevu od 1 do 5, gdje je spojni lanac amino kiseline od (b) SEQ ID NO: 51li SEQ ID NO: 6.
The methods comprise: (g) reacting Compound (A): 
(g) reakciji Spoja (A) 20
A method for inducing T cell activation in a subject, comprising administering to a subject in need of T cell activation an antibody comprising at least two binding domains, wherein a first binding domain binds to a first receptor of the tumor necrosis factor (TNF) superfamily and a second binding domain binds to a second receptor of the TNF superfamily, wherein the first receptor and the second receptor are different, 
Vezno sredstvo koje sadrži najmanje dvije vezne domene, a prva vezna domena veže se prvi receptor superfamilije faktora nekroze tumora (TNF), a druga vezna domena veže se za drugi receptor superfamilije TNF-a, pri čemu se prva vezna domena veže za CD40 i druga vezna domena se veže za 4-1BB (CD137), naznačeno time što je vezno sredstvo bispecifično protutijelo, gdje je vezno sredstvo agonističko vezno sredstvo, pri čemu je prva domena vezanja koji se veže za CD40 odabran iz prve skupine sastavljene od:
A kit of any of claims 21 to 32 further comprising any reagent suitable for use in the metagenomic or qPCR analysis of the DNA content of a sample. 
Pribor 1z bilo kojeg od zahtjeva 6 do 11 dalje sadržeći bilo koji reagens prikladan za korištenje u metagenomskoj ili qPCR analizi DNK sadržaja uzorka hrane.
R1, o, and p are as defined for compounds 2a and 3a above. 
, o i p su kako je prethodno definirano za spojeve 2a i 3a.
JNK inhibitor comprising an inhibitory peptide sequence according to the following general formula: 
JNK inhibitor koji sadrži inhibirajuću peptidnu sekvencu prema sljedećoj općoj formuli
The nitrile (AF) is treated with an excess of borane-THF solution in a solvent like THF at low temperature, followed by oxidation with hydrogen peroxide in the presence of sodium hydroxide to give a 1:1 mixture of alcohols shown as (AG′) and (AG″). 
Nitril (AF) se tretira sa suviškom boran-THF otopine u otapalu poput THF pri niskoj temperaturi, nakon čega slijedi oksidacija s vodikovim peroksidom u prisutnosti natrij hidroksida da bi se dobila 1:1 smjesa alkohola prikazana kao (AG') i (AG"').
BAC as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.00001 w/v% but less than 0.0035 w/v%; and water, wherein the composition satisfies Ph. 
BAC kao antimikrobni konzervans, te je koncentracija BAC u pripravku veća od 0,00001 m/v% ali manja od 0,0035 m/v%; i vodu, pri čemu je terapeutsko sredstvo suspendirano u otopini, i pri čemu se osmolalnost suspenzije nalazi u rasponu od 240 do 360 mOsm.
Process according to claim 4, which further comprises continuing the reaction of the dimethyl ketal of atorvastatin tert.-butyl ester (I) with the acid for 3 to 24 h at the same temperature to conclude the reaction. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se dodatno sastoji u nastavljanju reakcije dimetil-ketala tert-butilnog estera atorvastatina (I) s kiselinom u trajanju od 3 do 24 sata na istoj temperaturi kako bi se dovršilo reakciju.
A crystalline structure of a compound of formula II which is the (S)-propylene glycol solvate or the (R)-propylene glycol solvate or a mixture thereof, wherein R1, R2 and R2a are independently hydrogen, OH, OR5, alkyl, -OCHF2, -OCF3, -SR5a or halogen; 
22. Kristalna struktura spoja s formulom II li koja je (S)-propilen glikol solvat ili (R)-propilen glikol solvat ili njihova smjesa, naznačena time da
The use of Claims 17 or 18, wherein a therapeutically effective amount of the aripiprazole is present in the plasma of the individual for at least 7 days. 
Uporaba prema zahtjevu 17 ili 18, gdje se terapijski učinkovita količina aripiprazola zadržava u plazmi pojedinca najmanje 7 dana.
The reaction mixture was concentrated in vacuo and azeotroped with toluene (3×). 
Reakcijska smjesa se koncentrira in vacuo i azotira toluenom (3x).
A method for the preparation of expanded thermoplastic microspheres from unexpanded thermally expandable thermoplastic microspheres comprising a thermoplastic polymer shell encapsulating a blowing agent, said method comprising: 
Postupak priprave -ekspandiranih termoplastičnih mikrosfera od neekspandiranih toplinski rastezljivih termoplastičnih mikrosfera koje se sastoje od ljuske od termoplastičnog polimera koja okružuje sredstvo za rastezanje, naznačen time što se navedeni postupak sastoji u:
The method of claim 1, wherein the subject is in complete clinical remission after diagnosis of node positive or node negative breast cancer. The method of claim 1, wherein the subject is in partial clinical remission for breast cancer. 
Pripravak prema bilo kojem zahtjevu od 1 do 11, naznačen time da je subjekt u potpunoj kliničkoj remisiji nakon dijagnoze pozitivnog čvora ili negativnog čvora raka dojke, ili pri čemu je subjekt u djelomičnoj remisiji raka dojke.
The transgenic mouse of claim 3, wherein the human FcYRIIIA a-chain protein is expressed on NK cells of the mouse. 
Miš prema zahtjevu 2, naznačen time, što se humani FcyRIIA izražava na NK stanicama miša.
the diphtheria antigen in the form of diphtheria toxin D, 
- antigen difterije u obliku toksina difterije D,
The composition for the use of claim 7, wherein the TLR-3 agonist is a nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs: 3, 4, 5, 8, 9, 10, 11, and 12. 
Pripravak za primjenu prema zahtjevu 7, naznačen time, što agonist TLR-3 predstavlja nukleinsku kiselinu koja se sastoji od sekvencije odabrane iz grupe koja se sastoji od SEQ ID br.: 3, 4, 5, 8,9, 10, 11112.
The solution acidified to pH 3-4 using concentrated HCl and the resulting suspension is filtered, washed with water and then dried in vacuo. 
Otopinu se zakiseli na pH 3-4 upotrebom koncentrirane HCI i dobivenu suspenziju se profiltrira, ispere s vodom i zatim se osuši u vakuumu.
The thermoplastic film according to any preceding numbered embodiment, wherein each of said fibres covers an area of the base film of more than 4.5mm2, preferably more than 6.0mm2, most preferably more than 8.0mm2. 
Termoplastična folija sukladno bilo kojem od prethodnih zahtjeva, pri čemu svako od vlakana pokriva površinu veću od 4. Smm, poželjno više od 6.0 mm?, najbolje više od 8.0 mm.
System for covering of glass surfaces with a composition based on tin tetrachloride anhydrous according to the claim 8 wherein the system includes a mechanism for temperature control (16) with a thermostat which it registers at any time the temperature inside the tunnel (1) and that it is programmed by a temperature of control below which the mechanism of control interrupts automatically the supply of electricity to the dosing pump (7), interrupting the pulverization of mixture of composition based on tin tetrachloride anhydrous and air to the interior of the tunnel (1). 
Sistem za prekrivanje staklenih površina sa kompozicijom baziranom na bezvodnom kositar tetrakloridu prema patentnom zahtjevu 8 pri čemu sistem uključuje mehanizam (16) za kontrolu temperature sa termostatom koji registrira u bilo koje vrijeme temperaturu unutar tunela (1) i koji je programiran pomoću temperature kontrole ispod koje mehanizam kontrole automatski prekida opskrbu električnom energijom pumpe (7) za doziranje, prekidajući raspršivanje smjese kompozicije bazirane na bezvodnom kositar tetrakloridu i zraka u unutrašnjosti tunela (1).
The emulsion of claim 1, wherein the high HLB non-ionic hydrophilic surfactant is present at a concentration of 0.4% to 1.2% expressed as a weight by volume of emulsion (w/v), and wherein the percentage of the surfactants is from about 4% to about 8% weight/volume. 
Sastav cjepiva prema zahtjevu 1, naznačen time, da je neionski hidrofilni tenzid visoke HLB-vrijednosti prisutan s koncentracijom od 0,1% do 1,5% izraženom kao masa po volumenu emulzije (masa/volumen), i pri čemu je ukupna koncentracija tenzida od 4% do oko 8% prema masi po volumenu emulzije (masa/volumen).
The composition in a) may be purified by crystallization. 
Smjesa iz a) se može pročistiti kristalizacijom.
Preferred as excipients (b) are lactose monohydate, microcrystalline cellulose, powdered cellulose, dextrates (hydrated), lactitol (hydrated), siliconised microcrystalline cellulose, sacharose, calcium hydrogen phosphate, calcium carbonate, calcium lactate, or mixtures thereof. 
Kao ekscipijensi (b) poželjni su monohidratna laktoza, mikrokristalna celuloza, celuloza u prahu, dekstrati (hidrirani), laktitol (hidriran), silikonizirana mikrokristalna celuloza, saharoza, kalcijev hidrogen fosfat, kalcijev karbonat, kalcijev laktat, ili smjese istih.
the stream of products derived from the oxychlorination reactor, from which the 1,2-dichloroethane has been extracted, optionally containing an additional stream of ethane previously introduced in one of steps b) to f), is optionally recycled to step a) after having been optionally purged of gases and/or after an optional additional treatment in order to eliminate the chlorinated products contained therein; the 1,2-dichloroethane obtained is subjected to a pyrolysis thus producing vinyl chloride. 
HR P20110849 T1 struja produkata dobivenih iz reaktora za oksidaciju za kloriranje, iz koje je ekstrahiran 1,2-dikloroetan, proizvoljno sadrži dodatnu struju etana koja je prethodno uvedena u jednom od koraka b) do £f), se proizvoljno Teciklira u korak a) nakon što je proizvoljno očišćena od plinova i/ili nakon proizvoljne dodatne obrade kako bi se uklonili u njemu sadržani klorirani produkti; 1 dobiveni 1,2-dikloroetan je podvrgnut pirolizi te se tako dobiva vinil klorid.
A composition according to clause 13, wherein the polymeric moiety is present in an amount in the range of from 3% (w/v) to 20% (w/v). 
Smjesa prema zahtjevu 3, gdje je polimerni dio prisutan u količini u rasponu od 3% (t/v) do 20% (t/v).
A method for treating and/or preventing a cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of claim 1 . The method according to claim 14, wherein the pharmaceutical composition is an anti-cancer vaccine. 
Terapijski učinkovita količina farmaceutskog sastava iz bilo kojeg od prethodnih zahtjeva za uporabu u liječenju ili sprječavanju karcinoma kod pacijenata, Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
Functionally, the sugar replacement composition according to the invention is perfectly able to replace sugar in these meat applications. 
Funkcionalno, sastavina koja prema ovom izumu zamjenjuje šećer, idealna je zamjena za šećer u tim mesnim proizvodima.
or wherein the chimeric protein comprises the formula: 
ili pri čemu kimerni protein ima formulu:
Bicycle according to one of the aspects 2 to 13, 16 and 20, wherein a bottom tube structure results from the combination of the auxiliary motor and bottom tube, which does not exceed a width of 9 cm, 7 cm, 5 cm in a random sectional plane perpendicular to the longitudinal axis of the bottom tube. 
Bicikl (50) u skladu s patentnim zahtjevom 1, naznačen time što kombinacija pomoćnog motora (60) i donje cijevi (56) čini strukturu donje cijevi koja ne prelazi širinu od 9 cm, 7 cm, 5 cm u nasumičnoj ravnini poprečnog presjeka koja je okomita na uzdužnu os donje cijevi (56).
Compositions comprising an antibody, or antigen-binding portion thereof, or immunoconjugate or bispecific molecule of the invention and a pharmaceutically acceptable carrier are also provided. 
Kompozicija koja sadrži antitijelo ili antigen-vežući dio prema bilo kojem od patentnih zahtjeva 1 do 4, imunokonjugat prema patentnom zahtjevu 6 ili bispecifičnu molekulu prema patentnom zahtjevu 7, i farmaceutski prihvatljiv nosač.
wherein the anti-PD-1 antibody is for being administered prior to administration of the anti-KIR antibody on Days 1 and 29 and the anti-KIR antibody is for being administered within 30 minutes of the anti-PD-1 antibody. 
gdje anti-PD-1 antitijelo je za administraciju prije administracije anti-KIR antitijela na dane 1 i 29 i anti-KIR antitijelo je za administraciju u okviru 30 minuta anti-PD-1 antitijela.
A compound that binds to and activates the erythropoietin receptor (EPO-R), which compound comprises a peptide dimer having the formula: where 
Spoj koji se veže na 1 aktivira eritropoetinski receptor (EPO-R), gdje navedeni spoj sadrži peptidni dimer formule: ee.
The suspension is filtered on a Nytran 0.2 micrometer filter and washed with pure water and ethanol. 
Suspenzija je filtrirana na Nytran 0.2 mikrometraskom filteru i prane čistom vodom i etanolom.
Compound according to any of Claims 1-5, wherein the KIT dependent disease is selected from mast cell diseases, acute myelogenous leukemia, gastrointestinal stromal tumors, seminomas and dysgerminomas. 
Spoj u skladu s bilo kojim zahtjevom 1 do 5, naznačen time, da je KIT ovisno oboljenje izabrano između oboljenja mastocita, akutne mijelogene leukemije, gastrointestinalnih stroma tumora, seminoma i disgerminoma. t>&
transferring said hydrogen gas via open split interface (23) to the isotopic ratio mass spectrometer IRMS (26); and measuring the isotopic ratio of said hydrogen gas. 
- prenošenje navedenog plinovitog vodika putem sučelja sa otvorenim razdjelnikom (23) u maseni spektrometar za razlučivanje omjera izotopa IRMS (26); 1
Process according to any one of claims 1 to 15, characterized in that the aqueous solution comprising at least one earth alkali hydrogen carbonate that is obtained in step e) or step f) has a turbidity value of lower than 1.0 NTU, preferably of lower than 0.5 NTU, and most preferably of lower than 0.3 NTU. 
Postupak prema bilo kojem od zahtjeva 1 do 14, naznačen time da vodena otopina koja sadrži barem jedan zemnoalkalijski hidrogenkarbonat koja se dobiva u koraku e) ima vrijednost zamućenja manju od 0.5 NTU, te poželjno manju od 0.3 NTU.
An isolated polypeptide comprising an amino acid sequence of an immunoglobulin heavy chain having SEQ ID NO: 1, and an immunoglobulin light chain having SEQ ID NO: 2, and wherein a targeting antibody comprising said immunoglobulin heavy chain and said immunoglobulin light chain targets CD138. 
Imunokonjugat u skladu s patentnim zahtjevom 1, naznačen time što konstruirano ciljano protutijelo sadrži teški lanac koji ima SEQ ID NO: 1 i laki lanac koji ima SEQ ID NO: 2.